Genmab

Genmab, which is developing the drug with GlaxoSmithKline PLC, said it aims to submit the drug, called ofatumumab, for U.S. and European regulatory approval by the end of this year.

Genmab's Cancer Treatment 2008

Genmab, which is developing drugs designed to treat head and neck cancer, bought the plant at a time when the economy was different and it was more difficult to find contract manufacturers capable of meeting the company's drug production needs, Drakeman said.

Los Angeles Business News - Local Los Angeles News | Los Angeles Business from bizjournals 2009

Genmab shares slumped 20.4% in Copenhagen after the Danish drug maker said that top-line results from a zalutumumab Phase III study in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who failed standard platinum-based chemotherapy didn't meet its primary endpoint of demonstrating a statistically significant difference in overall survival.

European Stocks Finish Flat Ishaq Siddiqi 2010

Genmab shares slumped 20.4% in Copenhagen after the Danish drug maker said that top-line results from a zalutumumab Phase III study in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who failed standard platinum-based chemotherapy didn't meet its primary endpoint of demonstrating a statistically significant difference in overall survival.

European Stocks Finish Flat Ishaq Siddiqi 2010

Genmab shares surged 33% in Copenhagen amid market speculation that

Euro-zone Output Boosts Stocks; BP Slides 2010

Genmab shares slumped 20.4% in Copenhagen after the Danish drug maker said that top-line results from a zalutumumab Phase III study in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who failed standard platinum-based chemotherapy didn't meet its primary endpoint of demonstrating a statistically significant difference in overall survival.

European Stocks Finish Flat Ishaq Siddiqi 2010

Genmab said it and Glaxo will continue to review the results of the non-Hodgkin's lymphoma study and discuss the development strategy for Arzerra in the treatment of the condition, which is also known as ofatumumab.

Genmab, Glaxo Drug Disappoints in Study 2009

The poor results in the treatment of non-Hodgkin's lymphoma could mean that Glaxo and Genmab will have a harder time positioning Arzerra as a rival to Rituxan, the widely used drug sold by Roche Holding AG and Biogen Idec Inc.

Genmab, Glaxo Drug Disappoints in Study 2009

Genmab is developing the drug, Arzerra, with GlaxoSmithKline PLC.

Genmab, Glaxo Drug Disappoints in Study 2009

Genmab plunged 30% after the biotech firm reported that patients suffering from non-Hodgkin's lymphoma showed a lower-than-expected overall response rate in a trial of the firm's Arzerra drug.

Asia and Europe Rally After Rout 2009